» Articles » PMID: 33987291

A Path to Successful Patient Outcomes Through Aerosol Drug Delivery to Children: a Narrative Review

Overview
Journal Ann Transl Med
Date 2021 May 14
PMID 33987291
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Although using aerosolized medications is a mainstay of treatment in children with asthma and other respiratory diseases, there are many issues in terms of device and interface selection, delivery technique and dosing, as well as patient and parental education that have not changed for half a century. Also, due to many aerosol devices and interfaces available on the market and the broad range of patient characteristics and requirements, providing effective aerosol therapy to children becomes a challenge. While aerosol delivery devices are equally effective, if they are age-appropriate and used correctly, the majority of aerosol devices require multiple steps to be used efficiently. Unfortunately, many children with pulmonary diseases have problems with the correct delivery technique and do not gain therapeutic benefits from therapy that result in poor disease management and increased healthcare costs. Therefore, the purpose of this paper is to review the current knowledge on aerosol delivery devices used in children and guide clinicians on the optimum device- and interface-selection, delivery technique, and dosing in this patient population. Strategies on how to deliver aerosolized medications in crying and distressed children and how to educate parents on aerosol therapy and promote patient adherence to prescribed medications are also provided. Future directions of aerosol therapy in children should focus on these issues and implement policies and clinical practices that highlight the potential solutions to these problems.

Citing Articles

Recent Developments in Aerosol Pulmonary Drug Delivery: New Technologies, New Cargos, and New Targets.

Woodward I, Fromen C Annu Rev Biomed Eng. 2024; 26(1):307-330.

PMID: 38424089 PMC: 11222059. DOI: 10.1146/annurev-bioeng-110122-010848.


From the infant to the geriatric patient-Strategies for inhalation therapy in asthma and chronic obstructive pulmonary disease.

Hagmeyer L, van Koningsbruggen-Rietschel S, Matthes S, Rietschel E, Randerath W Clin Respir J. 2023; 17(6):487-498.

PMID: 37054701 PMC: 10265176. DOI: 10.1111/crj.13610.


Pharmacological Strategies and Recent Advancement in Nano-Drug Delivery for Targeting Asthma.

Ahmad A Life (Basel). 2022; 12(4).

PMID: 35455087 PMC: 9032250. DOI: 10.3390/life12040596.


Reconciling Oxygen and Aerosol Delivery with a Hood on In Vitro Infant and Paediatric Models.

Chen S, Chang H, Chien M, Xi J, Lin H Pharmaceutics. 2022; 14(1).

PMID: 35056987 PMC: 8779027. DOI: 10.3390/pharmaceutics14010091.


Quantifying Delivered Dose with Jet and Mesh Nebulizers during Spontaneous Breathing, Noninvasive Ventilation, and Mechanical Ventilation in a Simulated Pediatric Lung Model with Exhaled Humidity.

Ari A, Fink J Pharmaceutics. 2021; 13(8).

PMID: 34452139 PMC: 8400423. DOI: 10.3390/pharmaceutics13081179.

References
1.
Berg E, Picard R . In vitro delivery of budesonide from 30 jet nebulizer/compressor combinations using infant and child breathing patterns. Respir Care. 2009; 54(12):1671-8. View

2.
Reminiac F, Vecellio L, Bodet-Contentin L, Gissot V, Le Pennec D, Salmon Gandonniere C . Nasal high-flow bronchodilator nebulization: a randomized cross-over study. Ann Intensive Care. 2018; 8(1):128. PMC: 6301902. DOI: 10.1186/s13613-018-0473-8. View

3.
Ari A, Fink J . Recent advances in aerosol devices for the delivery of inhaled medications. Expert Opin Drug Deliv. 2020; 17(2):133-144. DOI: 10.1080/17425247.2020.1712356. View

4.
de Benedictis F, Selvaggio D . Use of inhaler devices in pediatric asthma. Paediatr Drugs. 2003; 5(9):629-38. DOI: 10.2165/00148581-200305090-00005. View

5.
Amirav I, Newhouse M . Review of optimal characteristics of face-masks for valved-holding chambers (VHCs). Pediatr Pulmonol. 2008; 43(3):268-74. DOI: 10.1002/ppul.20767. View